CytomX Therapeutics (NASDAQ:CTMX) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

CytomX Therapeutics (NASDAQ:CTMX) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04, FiscalAI reports. CytomX Therapeutics had a negative return on equity of 54.37% and a negative net margin of 166.40%.The business had revenue of $10.26 million during the quarter, compared to analysts’ expectations of $4.68 million.

Here are the key takeaways from CytomX Therapeutics’ conference call:

• Varseta‑M20%–32% and median progression‑free survival of ~7 months, positioning it as a potentially company‑building, first‑in‑class EpCAM ADC.
• Enrollment in dose‑optimization is complete (40 patients at 8.6 mg/kg and 10 mg/kg; 113 total in the Phase I), and management is targeting a registrational late‑line CRC study in the first half of 2027 with a comprehensive Phase I update planned in H2 2026 to inform dose selection.
• Updated adverse‑event management (prophylactic loperamide and budesonide, adjusted ideal body weight dosing) appears to lower high‑grade diarrhea (initially ~10% in early optimization patients), but longer follow‑up and broader data are needed to confirm tolerability and impact on overall survival.
• CytomX is advancing Varseta‑M into combination studies—bevacizumab combo data expected by H1 2027 and a chemo (bevacizumab + 5‑FU/leucovorin) Phase I/II starting in H2 2026—and plans Phase I expansions in other EpCAM‑expressing tumors to pursue pan‑tumor potential.
• Following a March financing, CytomX ended Q1 with $346.7M in cash and expects runway into at least H2 2028, which management says is sufficient to advance Varseta‑M into a registrational study and support planned clinical milestones.

CytomX Therapeutics Trading Down 0.5%

Shares of CTMX traded down $0.02 during midday trading on Friday, reaching $3.98. 5,054,790 shares of the company were exchanged, compared to its average volume of 3,705,994. CytomX Therapeutics has a 1-year low of $0.91 and a 1-year high of $8.21. The stock has a 50-day moving average price of $4.66 and a 200-day moving average price of $4.53. The company has a market cap of $677.36 million, a price-to-earnings ratio of -9.71 and a beta of 2.18.

Insider Transactions at CytomX Therapeutics

In other news, CFO Christopher Ogden sold 19,323 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $124,053.66. Following the completion of the transaction, the chief financial officer directly owned 296,948 shares of the company’s stock, valued at approximately $1,906,406.16. This represents a 6.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Yu-Waye Chu sold 21,279 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $136,611.18. Following the transaction, the insider directly owned 189,446 shares of the company’s stock, valued at approximately $1,216,243.32. The trade was a 10.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 191,063 shares of company stock worth $1,226,624 in the last quarter. Insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CTMX. Goldman Sachs Group Inc. acquired a new stake in CytomX Therapeutics during the first quarter valued at approximately $39,000. Woodline Partners LP acquired a new position in shares of CytomX Therapeutics in the 1st quarter valued at $1,054,000. Geode Capital Management LLC grew its holdings in shares of CytomX Therapeutics by 103.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock valued at $3,963,000 after buying an additional 887,218 shares during the period. Invesco Ltd. acquired a new position in CytomX Therapeutics in the 2nd quarter worth $32,000. Finally, Marshall Wace LLP lifted its position in CytomX Therapeutics by 2,650.9% during the 2nd quarter. Marshall Wace LLP now owns 2,353,122 shares of the biotechnology company’s stock worth $5,342,000 after buying an additional 2,267,583 shares in the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CTMX shares. Wedbush lifted their price target on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, March 17th. HC Wainwright lifted their price objective on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Weiss Ratings cut CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, March 19th. Wall Street Zen cut CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, April 25th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a report on Monday, March 16th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.44.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.